Jackie Bosch1, Martin O'Donnell2, Balakumar Swaminathan2, Eva Marie Lonn2, Mikul Sharma2, Gilles Dagenais2, Rafael Diaz2, Kamlesh Khunti2, Basil S Lewis2, Alvaro Avezum2, Claes Held2, Matyas Keltai2, Christopher Reid2, William D Toff2, Antonio Dans2, Lawrence A Leiter2, Karen Sliwa2, Shun Fu Lee2, Janice M Pogue2, Robert Hart2, Salim Yusuf2. 1. From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Québec (G.D.), Université Laval, Québec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), São Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa. boschj@mcmaster.ca. 2. From the Population Health Research Institute (J.B., M. O., B.S., E.M.L., M.S., S.F.L., J.M.P., R.H., S.Y.) and Hamilton Health Sciences (J.B.), School of Rehabilitation Science, McMaster University, Ontario; Institut Universitaire de Cardiologie et Pneumologie de Québec (G.D.), Université Laval, Québec; Li Ka Shing Knowledge Institute (L.A.L.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Research Board Clinical Research Facility (M.O.), Department of Medicine, NUI Galway, Ireland; Instituto Cardiovascular de Rosario (R.D.), Argentina; Diabetes Research Centre (K.K.), University of Leicester; Department of Cardiovascular Sciences and the National Institute for Health Research (W.D.T.), Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, UK; College of Medicine (A.D.), University of the Philippines, Manila, Philippines; Lady Davis Carmel Medical Center (B.S.L.), Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa; Dante Pazzanese Institute of Cardiology (A.A.), São Paulo, Brazil; Department of Medical Sciences (C.H.), Cardiology, Uppsala Clinical Research Center, Uppsala University, Sweden; Semmelweis University (M.K.), Budapest, Hungary; Monash University (C.R.), Melbourne, Victoria; School of Public Health (C.M.R.), Curtin University, Perth, Australia; and Hatter Institute for Cardiovascular Research in Africa (K.S.), Department of Medicine, University of Cape Town, Soweto Cardiovascular Research Group, South Africa.
Abstract
OBJECTIVE: To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk. METHODS: The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 × 2 factorial design. Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo. Participants who were ≥70 years of age completed the Digit Symbol Substitution Test (DSST), the modified Montreal Cognitive Assessment, and the Trail Making Test Part B at baseline and study end. RESULTS: Cognitive assessments were completed by 2,361 participants from 228 centers in 21 countries. Compared with placebo, candesartan/hydrochlorothiazide reduced systolic blood pressure by 6.0 mm Hg, and rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL. Participants were followed up for 5.7 years (median), and 1,626 completed both baseline and study-end assessments. Mean participant age was 74 years (SD ±3.5 years); 59% were women; 45% had hypertension; and 24% had ≥12 years of education. The mean difference in change in DSST scores was -0.91 (95% confidence interval [CI] -2.25 to 0.42) for candesartan/hydrochlorothiazide compared with placebo, -0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo, and -1.43 (95% CI -3.37 to 0.50) for combination therapy vs double placebo. No significant differences were found for other measures. CONCLUSIONS: Long-term blood pressure lowering with candesartan plus hydrochlorothiazide, rosuvastatin, or their combination did not significantly affect cognitive decline in older people. CLINICALTRIALSGOV IDENTIFIER: NCT00468923. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for older people, candesartan plus hydrochlorothiazide, rosuvastatin, or their combination does not significantly affect cognitive decline.
OBJECTIVE: To assess whether long-term treatment with candesartan/hydrochlorothiazide, rosuvastatin, or their combination can slow cognitive decline in older people at intermediate cardiovascular risk. METHODS: The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study was a double-blind, randomized, placebo-controlled clinical trial using a 2 × 2 factorial design. Participants without known cardiovascular disease or need for treatment were randomized to candesartan (16 mg) plus hydrochlorothiazide (12.5 mg) or placebo and to rosuvastatin (10 mg) or placebo. Participants who were ≥70 years of age completed the Digit Symbol Substitution Test (DSST), the modified Montreal Cognitive Assessment, and the Trail Making Test Part B at baseline and study end. RESULTS: Cognitive assessments were completed by 2,361 participants from 228 centers in 21 countries. Compared with placebo, candesartan/hydrochlorothiazide reduced systolic blood pressure by 6.0 mm Hg, and rosuvastatin reduced low-density lipoprotein cholesterol by 24.8 mg/dL. Participants were followed up for 5.7 years (median), and 1,626 completed both baseline and study-end assessments. Mean participant age was 74 years (SD ±3.5 years); 59% were women; 45% had hypertension; and 24% had ≥12 years of education. The mean difference in change in DSST scores was -0.91 (95% confidence interval [CI] -2.25 to 0.42) for candesartan/hydrochlorothiazide compared with placebo, -0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo, and -1.43 (95% CI -3.37 to 0.50) for combination therapy vs double placebo. No significant differences were found for other measures. CONCLUSIONS: Long-term blood pressure lowering with candesartan plus hydrochlorothiazide, rosuvastatin, or their combination did not significantly affect cognitive decline in older people. CLINICALTRIALSGOV IDENTIFIER: NCT00468923. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for older people, candesartan plus hydrochlorothiazide, rosuvastatin, or their combination does not significantly affect cognitive decline.
Authors: Brian R Ott; Lori A Daiello; Issa J Dahabreh; Beth A Springate; Kimberly Bixby; Manjari Murali; Thomas A Trikalinos Journal: J Gen Intern Med Date: 2015-01-10 Impact factor: 5.128
Authors: Rebecca F Gottesman; Andrea L C Schneider; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura Coker; Josef Coresh; David Knopman; Melinda C Power; Andreea Rawlings; A Richey Sharrett; Lisa M Wruck; Thomas H Mosley Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Lee Ashendorf; Angela L Jefferson; Maureen K O'Connor; Christine Chaisson; Robert C Green; Robert A Stern Journal: Arch Clin Neuropsychol Date: 2008-02-21 Impact factor: 2.813
Authors: Hans-Christoph Diener; Ralph L Sacco; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon Journal: Lancet Neurol Date: 2008-08-29 Impact factor: 44.182
Authors: Salim Yusuf; Jackie Bosch; Gilles Dagenais; Jun Zhu; Denis Xavier; Lisheng Liu; Prem Pais; Patricio López-Jaramillo; Lawrence A Leiter; Antonio Dans; Alvaro Avezum; Leopoldo S Piegas; Alexander Parkhomenko; Katalin Keltai; Matyas Keltai; Karen Sliwa; Ron J G Peters; Claes Held; Irina Chazova; Khalid Yusoff; Basil S Lewis; Petr Jansky; Kamlesh Khunti; William D Toff; Christopher M Reid; John Varigos; Gregorio Sanchez-Vallejo; Robert McKelvie; Janice Pogue; Hyejung Jung; Peggy Gao; Rafael Diaz; Eva Lonn Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245
Authors: Anne B Newman; Nancy W Glynn; Christopher A Taylor; Paola Sebastiani; Thomas T Perls; Richard Mayeux; Kaare Christensen; Joseph M Zmuda; Sandra Barral; Joseph H Lee; Eleanor M Simonsick; Jeremy D Walston; Anatoli I Yashin; Evan Hadley Journal: Aging (Albany NY) Date: 2011-01 Impact factor: 5.682
Authors: Ana Filipa Macedo; Fiona Claire Taylor; Juan P Casas; Alma Adler; David Prieto-Merino; Shah Ebrahim Journal: BMC Med Date: 2014-03-22 Impact factor: 8.775
Authors: Taylor J Krivanek; Seth A Gale; Brittany M McFeeley; Casey M Nicastri; Kirk R Daffner Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan Journal: Alzheimers Dement Date: 2019-08-01 Impact factor: 21.566
Authors: Stephen R Rapp; Sarah A Gaussoin; Bonnie C Sachs; Gordon Chelune; Mark A Supiano; Alan J Lerner; Virginia G Wadley; Valarie M Wilson; Lawrence J Fine; Jeff C Whittle; Alexander P Auchus; Srinivasan Beddhu; Dan R Berlowitz; Adam P Bress; Karen C Johnson; Marie Krousel-Wood; Jennifer Martindale-Adams; Eliza C Miller; Dena E Rifkin; Joni K Snyder; Leonardo Tamariz; Dawn F Wolfgram; Maryjo L Cleveland; Mia Yang; Linda O Nichols; Robert Nick Bryan; David M Reboussin; Jeff D Williamson; Nicholas M Pajewski Journal: Lancet Neurol Date: 2020-11 Impact factor: 44.182